New ulcerative colitis drug enters first human safety trial
NCT ID NCT06681181
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial is testing a new drug called GSK4528287 for the first time in humans. The goal is to check for side effects and see how the drug behaves in the body. 48 healthy volunteers will receive a single dose, with the amount increased gradually in different groups. If it's safe, this could lead to future studies in people with ulcerative colitis.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GSK4528287
What this could lead to
If this drug proves safe, it could lead to a new treatment option for people with inflammatory bowel diseases like ulcerative colitis.
What could go wrong
This is a very early, small phase 1 trial in healthy volunteers, not patients. The drug may not work or could have side effects that stop further development.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLITIS, ULCERATIVE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Cambridge, CB2 0GG, United Kingdom